Search Results
Laboratory of Geriatric and Oncologic Neuroendocrinology Research, Istituto Auxologico Italiano IRCCS, Milan, Italy
Search for other papers by Giovanni Vitale in
Google Scholar
PubMed
Search for other papers by Alessandra Dicitore in
Google Scholar
PubMed
Search for other papers by Concetta Sciammarella in
Google Scholar
PubMed
Search for other papers by Sergio Di Molfetta in
Google Scholar
PubMed
Search for other papers by Manila Rubino in
Google Scholar
PubMed
Search for other papers by Antongiulio Faggiano in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
progression ( Rinke et al. 2009 , Caplin et al. 2014 ). Pasireotide is a second-generation multireceptor-targeted SSA with a broader spectrum of affinity with respect to octreotide and lanreotide for different receptor subtypes (SSTR1, 2, 3, 5
Search for other papers by Marta Araujo-Castro in
Google Scholar
PubMed
Search for other papers by Betina Biagetti in
Google Scholar
PubMed
Search for other papers by Edelmiro Menéndez Torre in
Google Scholar
PubMed
Search for other papers by Iría Novoa-Testa in
Google Scholar
PubMed
Search for other papers by Fernando Cordido in
Google Scholar
PubMed
Search for other papers by Eider Pascual-Corrales in
Google Scholar
PubMed
Search for other papers by Víctor Rodríguez Berrocal in
Google Scholar
PubMed
Search for other papers by Fernando Guerrero-Pérez in
Google Scholar
PubMed
Search for other papers by Almudena Vicente in
Google Scholar
PubMed
Search for other papers by Juan Carlos Percovich Hualpa in
Google Scholar
PubMed
Search for other papers by Rogelio García-Centeno in
Google Scholar
PubMed
Search for other papers by Laura González-Fernández in
Google Scholar
PubMed
Search for other papers by María Dolores Ollero García in
Google Scholar
PubMed
Search for other papers by Ana Irigaray Echarri in
Google Scholar
PubMed
Search for other papers by María Dolores Moure Rodríguez in
Google Scholar
PubMed
Search for other papers by Cristina Novo-Rodríguez in
Google Scholar
PubMed
Search for other papers by María Calatayud in
Google Scholar
PubMed
Search for other papers by Rocío Villar-Taibo in
Google Scholar
PubMed
Search for other papers by Ignacio Bernabéu in
Google Scholar
PubMed
Search for other papers by Cristina Alvarez-Escola in
Google Scholar
PubMed
Search for other papers by Pamela Benítez Valderrama in
Google Scholar
PubMed
Search for other papers by Carmen Tenorio-Jiménez in
Google Scholar
PubMed
Department of Medicine and Surgery, Universidad Cardenal Herrera-CEU, CEU Universities, Castellón, Spain
Search for other papers by Pablo Abellán Galiana in
Google Scholar
PubMed
Search for other papers by Eva Venegas in
Google Scholar
PubMed
Search for other papers by Inmaculada González-Molero in
Google Scholar
PubMed
Search for other papers by Pedro Iglesias in
Google Scholar
PubMed
Search for other papers by Concepción Blanco-Carrera in
Google Scholar
PubMed
Search for other papers by Fernando Vidal-Ostos De Lara in
Google Scholar
PubMed
Search for other papers by Paz de Miguel Novoa in
Google Scholar
PubMed
Search for other papers by Elena López Mezquita in
Google Scholar
PubMed
Search for other papers by Felicia Alexandra Hanzu in
Google Scholar
PubMed
Neurological Tissue Bank of the Biobank, FCRB-IDIBAPS-Hospital Clinic Barcelona, Barcelona, Spain
Search for other papers by Iban Aldecoa in
Google Scholar
PubMed
Search for other papers by Silvia Aznar in
Google Scholar
PubMed
Search for other papers by Cristina Lamas in
Google Scholar
PubMed
Department of Medicine, Universitat de Vic-Universitat Central de Catalunya, Vic, Spain
Search for other papers by Anna Aulinas in
Google Scholar
PubMed
Department of Medicine, Universitat de Vic-Universitat Central de Catalunya, Vic, Spain
Search for other papers by Queralt Asla in
Google Scholar
PubMed
Search for other papers by Paola Gracia Gimeno in
Google Scholar
PubMed
Search for other papers by José María Recio-Córdova in
Google Scholar
PubMed
Search for other papers by María Dolores Avilés-Pérez in
Google Scholar
PubMed
Search for other papers by Diego Asensio-Wandosell in
Google Scholar
PubMed
Search for other papers by Miguel Sampedro-Núñez in
Google Scholar
PubMed
Search for other papers by Rosa Cámara in
Google Scholar
PubMed
Search for other papers by Miguel Paja Fano in
Google Scholar
PubMed
Search for other papers by Ignacio Ruz-Caracuel in
Google Scholar
PubMed
Search for other papers by Carmen Fajardo in
Google Scholar
PubMed
Search for other papers by Mónica Marazuela in
Google Scholar
PubMed
Search for other papers by Manel Puig-Domingo in
Google Scholar
PubMed
biochemical control is not achieved with fg-SRLs, the next recommended step is to combine different treatment regimens or to consider ‘second-line’ therapies such as pegvisomant or pasireotide. Pegvisomant is the first and currently only clinically available
Search for other papers by M Cives in
Google Scholar
PubMed
Search for other papers by P L Kunz in
Google Scholar
PubMed
Search for other papers by B Morse in
Google Scholar
PubMed
Search for other papers by D Coppola in
Google Scholar
PubMed
Search for other papers by M J Schell in
Google Scholar
PubMed
Search for other papers by T Campos in
Google Scholar
PubMed
Search for other papers by P T Nguyen in
Google Scholar
PubMed
Search for other papers by P Nandoskar in
Google Scholar
PubMed
Search for other papers by V Khandelwal in
Google Scholar
PubMed
Search for other papers by J R Strosberg in
Google Scholar
PubMed
still unclear which specific somatostatin receptor (SSTR) subtypes are primarily active in the antiproliferative effect of SSAs ( Villaume et al . 2010 , Sidéris et al . 2012 ). Pasireotide is a novel multireceptor-targeted SSA with avid binding
Search for other papers by Adriana Albani in
Google Scholar
PubMed
Search for other papers by Luis Gustavo Perez-Rivas in
Google Scholar
PubMed
Search for other papers by Sicheng Tang in
Google Scholar
PubMed
Search for other papers by Julia Simon in
Google Scholar
PubMed
Search for other papers by Kristin Elisabeth Lucia in
Google Scholar
PubMed
Search for other papers by Paula Colón-Bolea in
Google Scholar
PubMed
Search for other papers by Jochen Schopohl in
Google Scholar
PubMed
Search for other papers by Sigrun Roeber in
Google Scholar
PubMed
Search for other papers by Michael Buchfelder in
Google Scholar
PubMed
Search for other papers by Roman Rotermund in
Google Scholar
PubMed
Search for other papers by Jörg Flitsch in
Google Scholar
PubMed
Search for other papers by Jun Thorsteinsdottir in
Google Scholar
PubMed
Search for other papers by Jochen Herms in
Google Scholar
PubMed
Medicover Neuroendocrinology, Munich, Germany
Search for other papers by Günter Stalla in
Google Scholar
PubMed
Search for other papers by Martin Reincke in
Google Scholar
PubMed
Search for other papers by Marily Theodoropoulou in
Google Scholar
PubMed
bilateral adrenalectomy ( Ritzel et al. 2013 , Pivonello et al. 2015 , Tritos & Biller 2018 , Feelders et al. 2019 ). The somatostatin analogue pasireotide is the only pituitary-targeting pharmaceutical that is approved for the treatment of
Aix-Marseille Université, Molecular Biology Laboratory, Aix-Marseille Université, Department of Internal Medicine and Center of Excellence for Biomedical Research, Endocrinology Department, Oncology Department, Surgery Department, Biopathology Department, Pathology Laboratory, Surgery Department, Department of Integrative Biology and Pharmacology, CNRS, CRN2M‐UMR 7286, Faculté de Médecine, Secteur Nord – CS80011, 51, Bd Pierre Dramard, 13344 Marseille Cedex 15, France
Search for other papers by Amira Mohamed in
Google Scholar
PubMed
Search for other papers by Marie-Pierre Blanchard in
Google Scholar
PubMed
Search for other papers by Manuela Albertelli in
Google Scholar
PubMed
Search for other papers by Federica Barbieri in
Google Scholar
PubMed
Aix-Marseille Université, Molecular Biology Laboratory, Aix-Marseille Université, Department of Internal Medicine and Center of Excellence for Biomedical Research, Endocrinology Department, Oncology Department, Surgery Department, Biopathology Department, Pathology Laboratory, Surgery Department, Department of Integrative Biology and Pharmacology, CNRS, CRN2M‐UMR 7286, Faculté de Médecine, Secteur Nord – CS80011, 51, Bd Pierre Dramard, 13344 Marseille Cedex 15, France
Search for other papers by Thierry Brue in
Google Scholar
PubMed
Search for other papers by Patricia Niccoli in
Google Scholar
PubMed
Search for other papers by Jean-Robert Delpero in
Google Scholar
PubMed
Search for other papers by Genevieve Monges in
Google Scholar
PubMed
Search for other papers by Stephane Garcia in
Google Scholar
PubMed
Search for other papers by Diego Ferone in
Google Scholar
PubMed
Search for other papers by Tullio Florio in
Google Scholar
PubMed
Aix-Marseille Université, Molecular Biology Laboratory, Aix-Marseille Université, Department of Internal Medicine and Center of Excellence for Biomedical Research, Endocrinology Department, Oncology Department, Surgery Department, Biopathology Department, Pathology Laboratory, Surgery Department, Department of Integrative Biology and Pharmacology, CNRS, CRN2M‐UMR 7286, Faculté de Médecine, Secteur Nord – CS80011, 51, Bd Pierre Dramard, 13344 Marseille Cedex 15, France
Search for other papers by Alain Enjalbert in
Google Scholar
PubMed
Search for other papers by Vincent Moutardier in
Google Scholar
PubMed
Search for other papers by Agnes Schonbrunn in
Google Scholar
PubMed
Search for other papers by Corinne Gerard in
Google Scholar
PubMed
Aix-Marseille Université, Molecular Biology Laboratory, Aix-Marseille Université, Department of Internal Medicine and Center of Excellence for Biomedical Research, Endocrinology Department, Oncology Department, Surgery Department, Biopathology Department, Pathology Laboratory, Surgery Department, Department of Integrative Biology and Pharmacology, CNRS, CRN2M‐UMR 7286, Faculté de Médecine, Secteur Nord – CS80011, 51, Bd Pierre Dramard, 13344 Marseille Cedex 15, France
Search for other papers by Anne Barlier in
Google Scholar
PubMed
Aix-Marseille Université, Molecular Biology Laboratory, Aix-Marseille Université, Department of Internal Medicine and Center of Excellence for Biomedical Research, Endocrinology Department, Oncology Department, Surgery Department, Biopathology Department, Pathology Laboratory, Surgery Department, Department of Integrative Biology and Pharmacology, CNRS, CRN2M‐UMR 7286, Faculté de Médecine, Secteur Nord – CS80011, 51, Bd Pierre Dramard, 13344 Marseille Cedex 15, France
Search for other papers by Alexandru Saveanu in
Google Scholar
PubMed
3 . The two commercial SSA, octreotide and lanreotide, are octapeptides that bind with high affinity to sst 2 and with moderate affinity to sst 5 . The failures of these classical SSA have led to the development of new SSA such as pasireotide. This
Search for other papers by Donatella Treppiedi in
Google Scholar
PubMed
Search for other papers by Genesio Di Muro in
Google Scholar
PubMed
Search for other papers by Giusy Marra in
Google Scholar
PubMed
Search for other papers by Anna Maria Barbieri in
Google Scholar
PubMed
Search for other papers by Federica Mangili in
Google Scholar
PubMed
Search for other papers by Rosa Catalano in
Google Scholar
PubMed
Search for other papers by Andreea Serban in
Google Scholar
PubMed
Search for other papers by Emanuele Ferrante in
Google Scholar
PubMed
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Neurosurgery Unit, Milan, Italy
Search for other papers by Marco Locatelli in
Google Scholar
PubMed
Department of Biomedical Sciences, Humanitas University, Milan, Italy
Search for other papers by Andrea G Lania in
Google Scholar
PubMed
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Endocrinology Unit, Milan, Italy
Search for other papers by Maura Arosio in
Google Scholar
PubMed
Search for other papers by Anna Spada in
Google Scholar
PubMed
Search for other papers by Erika Peverelli in
Google Scholar
PubMed
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Endocrinology Unit, Milan, Italy
Search for other papers by Giovanna Mantovani in
Google Scholar
PubMed
patients ( Nieman et al. 2015 ). In relapsed cases or when the surgery fails, the second generation somatostatin analog (SSA) pasireotide is used to pharmacologically target the tumor and lower ACTH and cortisol levels ( Bruns et al. 2002 , Lewis et
Search for other papers by Misu Lee in
Google Scholar
PubMed
Search for other papers by Amelie Lupp in
Google Scholar
PubMed
Search for other papers by Nigel Mendoza in
Google Scholar
PubMed
Search for other papers by Niamh Martin in
Google Scholar
PubMed
Search for other papers by Rudi Beschorner in
Google Scholar
PubMed
Search for other papers by Jürgen Honegger in
Google Scholar
PubMed
Search for other papers by Jürgen Schlegel in
Google Scholar
PubMed
Search for other papers by Talia Shively in
Google Scholar
PubMed
Search for other papers by Elke Pulz in
Google Scholar
PubMed
Search for other papers by Stefan Schulz in
Google Scholar
PubMed
Search for other papers by Federico Roncaroli in
Google Scholar
PubMed
Search for other papers by Natalia S Pellegata in
Google Scholar
PubMed
hormone and insulin-like growth factor 1 levels and induces tumor shrinkage ( Theodoropoulou & Stalla 2013 ). Owing to the restricted affinity of these two compounds for SSTRs, the multiligand SSA pasireotide was developed. Pasireotide has a 158-, >30
Search for other papers by Pedro Marques in
Google Scholar
PubMed
Search for other papers by Sayka Barry in
Google Scholar
PubMed
Search for other papers by Eivind Carlsen in
Google Scholar
PubMed
Search for other papers by David Collier in
Google Scholar
PubMed
Search for other papers by Amy Ronaldson in
Google Scholar
PubMed
Search for other papers by Sherine Awad in
Google Scholar
PubMed
Search for other papers by Neil Dorward in
Google Scholar
PubMed
Search for other papers by Joan Grieve in
Google Scholar
PubMed
Search for other papers by Nigel Mendoza in
Google Scholar
PubMed
Search for other papers by Samiul Muquit in
Google Scholar
PubMed
Search for other papers by Ashley B Grossman in
Google Scholar
PubMed
Search for other papers by Frances Balkwill in
Google Scholar
PubMed
Search for other papers by Márta Korbonits in
Google Scholar
PubMed
somatostatin receptor subtype 2, SST2) and second-generation (pasireotide activating SST1, SST2, SST3 and SST5) somatostatin analogues have been effectively used in the management of many types of PitNETs ( Ibanez-Costa & Korbonits 2017 , Gunther et al. 2018
Search for other papers by Jennifer A Chan in
Google Scholar
PubMed
Search for other papers by David P Ryan in
Google Scholar
PubMed
Search for other papers by Andrew X Zhu in
Google Scholar
PubMed
Search for other papers by Thomas A Abrams in
Google Scholar
PubMed
Search for other papers by Brian M Wolpin in
Google Scholar
PubMed
Search for other papers by Paige Malinowski in
Google Scholar
PubMed
Search for other papers by Eileen M Regan in
Google Scholar
PubMed
Search for other papers by Charles S Fuchs in
Google Scholar
PubMed
Search for other papers by Matthew H Kulke in
Google Scholar
PubMed
(sst 1–5) ( Lamberts 1991 ). Pasireotide (SOM230) is a multi-ligand somatostatin analog that has high binding affinity to the somatostatin receptors sst1, sst2, sst3, and sst5 ( Schmid 2008 ). Compared with octreotide, pasireotide has greater binding
Search for other papers by Sara Pusceddu in
Google Scholar
PubMed
Search for other papers by Antonio Facciorusso in
Google Scholar
PubMed
Search for other papers by Luca Giacomelli in
Google Scholar
PubMed
Search for other papers by Natalie Prinzi in
Google Scholar
PubMed
Search for other papers by Francesca Corti in
Google Scholar
PubMed
Search for other papers by Monica Niger in
Google Scholar
PubMed
Search for other papers by Massimo Milione in
Google Scholar
PubMed
Search for other papers by Jorgelina Coppa in
Google Scholar
PubMed
Search for other papers by Tommaso Cascella in
Google Scholar
PubMed
Search for other papers by Iolanda Pulice in
Google Scholar
PubMed
Search for other papers by Lavinia Biamonte in
Google Scholar
PubMed
Search for other papers by Simonetta Papa in
Google Scholar
PubMed
Search for other papers by Maria Di Bartolomeo in
Google Scholar
PubMed
Search for other papers by Aashni Shah in
Google Scholar
PubMed
Search for other papers by Rodolfo Sacco in
Google Scholar
PubMed
Oncology and Hemato-Oncology Department, Università degli Studi di Milano, Milan, Italy
Search for other papers by Filippo de Braud in
Google Scholar
PubMed
), which met the following inclusion criteria: (a) patients: adult patients with NETs treated with systemic therapies; (b) intervention: analogs (OCT, pasireotide, LAN), combination of everolimus plus SSAs, everolimus alone, sunitinib); (c) comparator